Short-Term Debt to Equity Ratio: Chromocell Therapeutics (CHRO)
This price chart illustrates the financial standing of Chromocell Therapeutics (CHRO), where the indicator stands at 0.00. Management of this micro-cap company is developing non-opioid analgesics despite a limited budget. The business relies on the study of ion channels, building valuable intellectual capital for future licensing deals. The startup is currently focusing on preclinical research, planning to attract a strategic partner to commercialize its molecules.
Metric breakdowns and analytics for chromocell.com (CHRO)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Chromocell Therapeutics|CHRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Chromocell Therapeutics Corp.|CHRO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Chromocell Therapeutics Corp|CHRO - Company Long-Term Loans and Borrowings|Company Short-Term Debt Chromocell Therapeutics|Quick Liquidity chromocell.com
- company profitability and valuation multiples indicators:
Fundamental valuation:CHRO Chromocell Therapeutics Corporation
This ratio assesses liquidity risk by comparing liabilities maturing within one year against equity, while the history of short-term debt relative to equity determines the company's reliance on quick loans, which is critical for Chromocell Therapeutics (CHRO), whose significant pricing power in the inelastic demand segment for non-opioid pain relief should ensure the stability of its financial structure.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amylyx AMLX|Ratio of Short-Term Indebtedness to Capital TRVI|PRAX - Short-Term Debt to Equity|Current Liabilities to Capital anavex.com|CeriBell (CBLL) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Prothena Biosciences|Short-Term Debt to Equity Alector Inc.|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Capital OMER|Short-Term Debt to Equity Ratio neurogene.com NGNE|Short-Term Debt to Capital ACIU (AC Immune SA)|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA - Short-Term Debt to Equity|SCLX: Short-Term Debt to Equity|Tevogen Bio Holdings (TVGN) - Short-Term Debt to Equity|ACOG (Alpha Cognition Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio CGTX|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio SAVA (Cassava)|Short-Term Loans to Capital Ratio ASRT|Short-Term Debt to Capital COYA (Coya Therapeutics)|Ratio of Short-Term Indebtedness to Capital VTGN|Ovid Rx - Short-Term Debt to Capital|Current Liabilities to Capital Acumen Pharmaceuticals Inc.|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Alterity Therapeutics Limited - Ratio of Short-Term Indebtedness to Capital|CLNN (Clene Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Jupiter Neurosciences (JUNS)|RLMD: Current Liabilities to Equity|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Current Liabilities to Capital|AIFF: Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Capital|NRSN (neurosense-tx.com) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Loans to Capital Ratio|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|NeurAxis Inc (NRXS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital HSDT|Short-Term Debt to Equity Ratio passagebio.com PASG|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|Short-Term Debt to Capital Coefficient Minerva Neurosciences Inc (NERV)|Athira - Short-Term Debt to Capital|Addex (ADXN) - Short-Term Debt to Equity Ratio|ALZN: Short-Term Debt to Capital|Cyclerion Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Protagenic Therapeutics Inc.|KTTA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cortigent, Inc. (CRGT)|ATXI - Current Liabilities to Capital|Short-Term Debt to Equity Brainstorm Cell BCLI|CARA: Short-Term Debt to Capital Ratio|Eliem - Short-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|Marinus Pharma (MRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX - Current Liabilities to Capital|Short-Term Debt to Capital TRVN (Trevena, Inc)|VIGL - Short-Term Debt to Equity Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)